Ivan Burkov

Junior Partner

2023

Principal

2022 - 2023

Board Director: Ambagon, Draupnir Bio, Salvia Bioelectronics Observer roles: Precirix, Quralis, NMD Pharma

Senior Associate

2019 - 2021

Healthcare investment team

Mentor

2017 - 2022

Advising selected startups of the Biomedical cluster at the Skolkovo Foundation - key Russian organization that fosters startups and venture capitals.

Summer Associate

2018 - 2018

Evaluated investment opportunities, supported ongoing fund's activities Created a comprehensive market model for one of the portfolio companies Conducted research on management turnover and strategic change in pharmaceutical industry

Business Development and Innovation manager

2017 - 2018

- Scouting and evaluation of post-POC opportunities to maximize top line growth of the regional affiliate and Global General Medicines & Emerging Markets business unit - Scouting and evaluation of early-stage regional R&D start-ups and technologies in line with Sanofi's global strategy - Support in execution of out- , in-licensing, M&As and other alliances deals - Leader of the internal project aimed at fostering innovative culture within the affiliate

Product planning manager Eurasia

2015 - 2016

- Significant geographical coverage (countries of the Eurasia region) - Prioritization and transfer of Sanofi's portfolio to the Eurasian Economic Union supranational regulatory environment - Integrative strategic activity in collaboration with various stakeholders (legal, patent, regulatory, medical, marketing, BD), aimed at securing brand business of Sanofi-Aventis portfolio. - Development and implementation of tools focused on enhancing branded/innovative product value, based on business and regulatory approaches. - Optimization of products life cycle through scientific and clinical evidence dissemination among internal and external stakeholders

Marie Curie Co-fund Postdoctoral fellow

2012 - 2015

I was leading an EU funded postdoc project that studied the roles of RNA translational regulation in cancer and metastasis. One of the purposes of the study was to evaluate novel biomarkers of cancer metastasis in order to create a method for its prediction and prevention.

Advisor

2013 - 2014

Organized the negotiation process between DanFur (Danish biotech startup) and Institute of Cytology and Genetics (Novosibirsk, Russia)

Consultant/advisor

2012 - 2014

I was responsible for the design of R&D activities aimed to improve the technological platform (transgenic animals producing human therapeutic proteins), writing of grants and proposals for fund-raising, preliminary patent and market research and helped to build strategic plan for the project. My contribution resulted in addition of new product (hGM-CSF) to the pipeline and progress of another (hG-CSF) to the stage of preclinical trials.

Research fellow

2008 - 2012

During this period, I have been involved in research activities within the laboratory. I have conducted a study on hybrid stem cells and PhD project on the production of therapeutic proteins in transgenic animals. Additionally, I have participated in a collaborative project with the Moscow Institute of bioorganic chemistry, where we generated of a schizophrenia transgenic mice model.